4.5 Review

Human prostate cancer heterotransplants: a review on this experimental model

Journal

ASIAN JOURNAL OF ANDROLOGY
Volume 12, Issue 4, Pages 509-518

Publisher

SHANGHAI INST MATERIA MEDICA
DOI: 10.1038/aja.2010.17

Keywords

cancer; experimental model; heterotransplant; nude mice; prostate; xenotransplant

Ask authors/readers for more resources

A common model used for preclinical research was in vitro human tumor cell culture. An alternative model was the direct implantation of a unique patient's tumor biopsy specimens into immunodeficient host mice. Published data from PubMed (http://www.ncbi.nlm.nih.gov) and Current Contents Connect databases (http://thomsonreuters.com/products_services/science/science_products/a-z/current_contents_connect) were reviewed. Prostate cancer (PCa) heterotransplantation was evaluated using histopathology, morphology, cell differentiation, DNA content, tumor marker expression, metastases, tumor kinetics, tumor take rate and tumor vasculature in the first tumor heterotransplant. The heterotransplanted tumor retained the biological properties of the original tumor, such as morphology, degree of differentiation, pathology, secretory activity, expression of tumor markers and human vasculature. Human PCa heterotransplants have considerable experimental advantages over cell culture following xenotransplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models

Lluis Lopez-Barcons, Barry J. Maurer, Min H. Kang, C. Patrick Reynolds

INTERNATIONAL JOURNAL OF CANCER (2017)

Review Andrology

Human benign prostatic hyperplasia heterotransplants as an experimental model

Lluis-A Lopez-Barcons

ASIAN JOURNAL OF ANDROLOGY (2010)

Article Hematology

Pegylated arginase I: a potential therapeutic approach in T-ALL

Claudia P. Hernandez, Kevin Morrow, Lluis A. Lopez-Barcons, Jovanny Zabaleta, Rosa Sierra, Cruz Velasco, John Cole, Paulo C. Rodriguez

BLOOD (2010)

Meeting Abstract Oncology

Enhanced activity of fenretinide/-LYM-X-SORB™ (4-HPR/LXS) oral powder in combination with ketoconazole and vincristine against recurrent neuroblastoma xenografts

Lluis Lopez-Barcons, Min H. Kang, Barry J. Maurerl, C. Patrick Reynolds

CANCER RESEARCH (2012)

Meeting Abstract Oncology

Radiation Induces Upregulation of GRP78 in Human Head and Neck Tumors

A. N. Ali, L. A. Lopez-Barcons, P. L. Feingold, G. Sica, M. Willard, S. Muller, R. Diaz

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)

Review Cell Biology

Serially heterotransplanted human prostate tumours as an experimental model

Lluis-A. Lopez-Barcons

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)

Article Oncology

The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide plus irinotecan against models of high-risk neuroblastoma

Ashly Hindle, Balakrishna Koneru, Monish Ram Makena, Lluis Lopez-Barcons, Wan Hsi Chen, Thinh H. Nguyen, C. Patrick Reynolds

Summary: High MGMT expression is associated with resistance to alkylating agents and TMZ+IRN in preclinical neuroblastoma models. The MGMT inhibitor O6BG enhances the anticancer effect of TMZ+IRN in vitro and in vivo.

ANTI-CANCER DRUGS (2021)

Article Biochemistry & Molecular Biology

Insights into the modular design of kinase inhibitors and application to Abl and Axl

Sameer Phadke, Lluis Lopez-Barcons, Nathalie Vandecan, Zhifen Wu, Taylor K. Johnson, Eric J. Lachacz, Sofia D. Merajver, Matthew B. Soellner

Summary: The study presents a design strategy to generate a combination of kinase inhibitors with different hinge-binders and DFG-pocket groups, and investigates their selectivity. Through analysis, two selective inhibitors with low nanomolar potency against Axl or clinically relevant mutants of Abl were identified.

RSC MEDICINAL CHEMISTRY (2022)

Meeting Abstract Oncology

MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.

Athena M. Apfel, Nathan M. Merrill, Nathalie M. Vandecan, Liwei Bao, Xu Cheng, Lluis A. Lopez-Barcons, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Matthew B. Soellner, Sofia D. Merajver

CANCER RESEARCH (2021)

Meeting Abstract Oncology

UM-9107: A selective wild-type and T315I Bcr-Abl inhibitor with in vivo activity against chronic myelogenous leukemia

Sameer Phadke, Lluis Lopez-Barcons, Taylor K. Johnson, Eric J. Lachacz, Sofia D. Merajver, Matthew B. Soellner

CANCER RESEARCH (2019)

Review Biochemistry & Molecular Biology

Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy

Lluis A. Lopez-Barcons, Arif N. Ali, Roberto Diaz

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)

Article Oncology

Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

Marie-Emmanuelle Legrier, Chia-Ping Huang Yang, Han-Guang Yan, Lluis Lopez-Barcons, Steven M. Keller, Roman Perez-Soler, Susan Band Horwitz, Hayley M. McDaid

CANCER RESEARCH (2007)

Meeting Abstract Oncology

Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation

H. M. McDaid, M. Legrier, C. H. Yang, H. G. Yan, L. Lopez-Barcons, S. M. Keller, S. B. Horwitz

JOURNAL OF CLINICAL ONCOLOGY (2007)

No Data Available